We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+8.61%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$1.87B
AUM Growth
+$33.8M
Cap. Flow
-$49.4M
Cap. Flow %
-2.64%
Top 10 Hldgs %
83.98%
Holding
25
New
1
Increased
9
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$28.8M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$25.9M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$8.56M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$6.8M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$5.78M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$42.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$28M
3
INCY icon
Incyte
INCY
+$23.6M
4
OPTR
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
+$17.9M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 87.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$343M 18.32%
4,058,542
+60,000
+2% +$4.75M
GILD icon
2
Gilead Sciences
GILD
$165B
$266M 14.23%
3,547,714
-80,000
-2% -$5.57M
IONS icon
3
Ionis Pharmaceuticals
IONS
$9.4B
$256M 13.66%
6,417,548
-785,037
-11% -$28M
INCY icon
4
Incyte
INCY
$24.4B
$214M 11.42%
4,221,087
-542,183
-11% -$23.6M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$126B
$104M 5.58%
1,404,445
– –
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$101M 5.38%
757,428
– –
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
$94.4M 5.05%
2,959,412
+60,000
+2% +$1.81M
HALO icon
8
Halozyme
HALO
$12.2B
$70.8M 3.78%
4,724,936
-791,386
-14% -$10.2M
PCYC
9
DELISTED
PHARMACYCLICS INC
PCYC
$67.3M 3.6%
636,542
+237,512
+60% +$28.8M
GEVA
10
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$55.6M 2.97%
858,757
+144,155
+20% +$8.56M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$80.8B
$52.8M 2.82%
192,000
+90,000
+88% +$25.9M
IMGN
12
DELISTED
Immunogen Inc
IMGN
$47.3M 2.53%
3,225,816
-50,000
-2% -$768K
INVA icon
13
Innoviva
INVA
$1.48B
$31.7M 1.69%
1,102,311
– –
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$29.3B
$30.3M 1.62%
471,288
– –
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$29.4M 1.57%
488,188
+106,302
+28% +$5.78M
ECYT
16
DELISTED
Endocyte, Inc. Common Stock
ECYT
$28.2M 1.51%
2,643,522
+374,177
+16% +$4.13M
NBIX icon
17
Neurocrine Biosciences
NBIX
$16.6B
$24.7M 1.32%
2,646,552
+696,404
+36% +$6.8M
INFI
18
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$18M 0.96%
1,300,737
– –
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$13.3M 0.71%
471,282
+97,982
+26% +$3.63M
ARIA
20
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$9.46M 0.51%
1,387,171
-2,301,900
-62% -$12.4M
IDIX
21
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
$7.47M 0.4%
1,250,000
– –
ACHN
22
DELISTED
Achillion Pharmaceuticals
ACHN
$5.91M 0.32%
1,779,340
– –
OPTR
23
DELISTED
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
– –
-1,422,200
Closed -$17.9M
ONXX
24
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
– –
-339,870
Closed -$42.4M

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2013 Portfolio in Review

As of Q4 2013, BB Biotech held 25 positions worth $1.87B, up 1.8% from $1.84B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

BB Biotech's Q4 2013 filing shows 1 new, 9 increased, 6 reduced and 2 closed positions. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $42.4M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier.

  • BB Biotech added most to PHARMACYCLICS INC in Q4 2013, an estimated $28.8M increase.
  • BB Biotech's biggest Q4 2013 reduction was Ionis Pharmaceuticals, cutting an estimated $28M.
  • BB Biotech fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $42.4M.
  • BB Biotech's ten largest holdings make up 84% of its $1.87B portfolio in Q4 2013.
  • BB Biotech opened 1 new position and closed 2 in Q4 2013.
  • BB Biotech's portfolio value rose 1.8% quarter-over-quarter to $1.87B.

Based on BB Biotech's 13F filing for Q4 2013, filed 12 Feb 2014.